Vaxart Appoints W. Mark Watson to its Board of Directors
August 08 2022 - 8:00AM
Vaxart, Inc. (NASDAQ: VXRT) today announced that W. Mark
Watson was appointed to the Company’s Board of Directors, effective
August 4, 2022.
Mr. Watson will become Chair of the Company’s Audit Committee,
effective October 1. Robert A. Yedid, a member of the Board and the
Audit Committee, was appointed Interim Chairperson of the Audit
Committee, to serve until Mr. Watson becomes Chair.
"We are very excited to welcome Mark to the Board, whose skills
and experience will help us advance our strategy to develop
potentially transformative oral pill vaccines,” said Andrei
Floroiu, Vaxart's Chief Executive Officer. "Mark’s
background, combining a highly regarded career in professional
services, deep financial and strategic acumen and board experience
with life sciences companies, will provide the Company with a
valuable perspective as we focus on achieving our corporate
goals.”
The Company also announced that after years of service and
dedication, Karen Wilson stepped down from the Board of Directors,
effective August 4, 2022. "We would like to express our
appreciation to Karen for her significant contributions to Vaxart
during her service on the Board of Directors and committees," said
Vaxart Board Chairman Todd C. Davis.
About W. Mark Watson
Mr. Watson is a Certified Public Accountant with over 40 years
of experience in public accounting and auditing, having spent his
entire career from January 1973 to June 2013 at Deloitte Touche
Tohmatsu and its predecessor, most recently as Central Florida
Marketplace Leader.
He has served as lead audit partner and lead client service
partner on public companies ranging from middle market firms to
Fortune 500 enterprises.
Mr. Watson also serves as Chairman of the Board of Directors and
Chairman of the Audit Committee of Inhibitor Therapeutics, Inc. He
previously served as a director and member of the Audit Committee
of Sykes Enterprises, Inc. and BioDelivery Sciences International,
Inc.
A member of American Institute of Certified Public Accountants
and the Florida Institute of Certified Public Accountants, Mr.
Watson is qualified to serve on the Board due to his expertise in
public accounting and his experience with life science and
pharmaceutical companies.
He received his undergraduate degree in Accounting from
Marquette University.
About Vaxart Vaxart is a
clinical-stage biotechnology company developing a range of oral
recombinant vaccines based on its proprietary delivery platform.
Vaxart vaccines are designed to be administered using tablets that
can be stored and shipped without refrigeration and eliminate the
risk of needle-stick injury. Vaxart believes that its proprietary
tablet vaccine delivery platform is suitable to deliver recombinant
vaccines, positioning the company to develop oral versions of
currently marketed vaccines and to design recombinant vaccines for
new indications. Vaxart’s development programs currently include
tablet vaccines designed to protect against coronavirus, norovirus,
seasonal influenza, and respiratory syncytial virus (RSV), as well
as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s
first immune-oncology indication. Vaxart has filed broad domestic
and international patent applications covering its proprietary
technology and creations for oral vaccination using adenovirus and
TLR3 agonists.
Note Regarding Forward-Looking
Statements This press release contains forward-looking
statements that involve substantial risks and uncertainties. All
statements, other than statements of historical facts, included in
this press release regarding Vaxart's strategy, prospects, plans
and objectives, results from preclinical and clinical trials,
commercialization agreements and licenses, and beliefs and
expectations of management are forward-looking statements. These
forward-looking statements may be accompanied by such words as
"should," "believe," "could," "potential," "will," "expected,"
“anticipate,” "plan," and other words and terms of similar meaning.
Examples of such statements include, but are not limited to,
statements relating to Vaxart's ability to develop and
commercialize its product candidates, including its vaccine booster
products; Vaxart's expectations regarding clinical results and
trial data; and Vaxart's expectations with respect to the
effectiveness of its product candidates. Vaxart may not actually
achieve the plans, carry out the intentions, or meet the
expectations or projections disclosed in the forward-looking
statements, and you should not place undue reliance on these
forward-looking statements. Actual results or events could differ
materially from the plans, intentions, expectations, and
projections disclosed in the forward-looking statements. Various
important factors could cause actual results or events to differ
materially from the forward-looking statements that Vaxart makes,
including uncertainties inherent in research and development,
including the ability to meet anticipated clinical endpoints,
commencement, and/or completion dates for clinical trials,
regulatory submission dates, regulatory approval dates, and/or
launch dates, as well as the possibility of unfavorable new
clinical data and further analyses of existing clinical data; the
risk that clinical trial data are subject to differing
interpretations and assessments by regulatory authorities; whether
regulatory authorities will be satisfied with the design of and
results from the clinical studies; decisions by regulatory
authorities impacting labeling, manufacturing processes, and safety
that could affect the availability or commercial potential of any
product candidate, including the possibility that Vaxart's product
candidates may not be approved by the FDA or non-U.S. regulatory
authorities; that, even if approved by the FDA or non-U.S.
regulatory authorities, Vaxart's product candidates may not achieve
broad market acceptance; that a Vaxart collaborator may not attain
development and commercial milestones; that Vaxart or its partners
may experience manufacturing issues and delays due to events
within, or outside of, Vaxart's or its partners' control;
difficulties in production, particularly in scaling up initial
production, including difficulties with production costs and
yields, quality control, including stability of the product
candidate and quality assurance testing, shortages of qualified
personnel or key raw materials, and compliance with strictly
enforced federal, state, and foreign regulations; that Vaxart may
not be able to obtain, maintain, and enforce necessary patent and
other intellectual property protection; that Vaxart's capital
resources may be inadequate; Vaxart's ability to resolve pending
legal matters; Vaxart's ability to obtain sufficient capital to
fund its operations on terms acceptable to Vaxart, if at all; the
impact of government healthcare proposals and policies; competitive
factors; and other risks described in the "Risk Factors" sections
of Vaxart's Quarterly and Annual Reports filed with the SEC. Vaxart
does not assume any obligation to update any forward-looking
statements, except as required by law.
Contacts
Vaxart Media Relations: |
Investor Relations: |
Mark Herr |
Andrew Blazier |
Vaxart, Inc. |
Finn Partners |
mherr@vaxart.com |
IR@Vaxart.com |
(203) 517-8957 |
(646) 871-8486 |
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Sep 2023 to Sep 2024